Immunome expects an FDA action date at the end of April in 2027 for Varagastat while preparing a global launch. Clinical data for multiple ADCs, including IM1021, are slated for ASH, with more data expected.
IMNM · Immunome Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 43%
- Latest filing
- 10-Q · Nov 9
- Price history
- Oct 2020 to Nov 2026
Latest documents
Immunome registered up to approximately $134.1 million of common stock for sale through TD Securities (USA) LLC or TD Cowen, replacing a prior $200.0 million agreement under which it sold 6,655,587 shares for gross proceeds of $65.9 million.
Immunome registered 4,425,487 common shares for BMS to resell after paying $20.0 million in cash for an amendment eliminating milestone and royalty obligations under its license agreement.
Immunome Inc. reported positive Phase 3 RINGSIDE results for varegacestat and said the FDA accepted its NDA, assigning a PDUFA target action date of April 28, 2027. The company has generated no product-sales revenue.
Immunome reported a net loss of $85.8 million for the quarter ended September 30, 2026, while varegacestat’s PDUFA target action date is April 28, 2027. IM-1340 received IND clearance, with its Phase 1 trial expected to start by year-end 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| IM-1021 | 9.58M | the three months ended September 30, 2026 filing | — |
| IM-1340 | 1.73M | the three months ended September 30, 2026 filing | — |
| IM-1617 | 1.63M | the three months ended September 30, 2026 filing | — |
| IM-3050 | 2.23M | the three months ended September 30, 2026 filing | — |
| Indirect research and development | 28.5M | the three months ended September 30, 2026 filing | — |
| objective response rate (B-NHL) | 53% | as of the June 26, 2026 abstract data cutoff | — |
| objective response rate (DLBCL) | 64% | as of the June 26, 2026 abstract data cutoff | — |
| Other | 13.27M | the three months ended September 30, 2026 filing | — |
| Total share-based compensation expense | 12.76M | the three months ended September 30, 2026 filing | — |
| Varegacestat | 12.58M | the three months ended September 30, 2026 filing | — |
| cash, cash equivalents and marketable securities | $520M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMNM
this stock
Immunome Inc.
|
$1.85B | -27.0% | -23.2% | — | 13.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 18
Immunome expects an FDA action date at the end of April in 2027 for Varagastat while preparing a global launch. Clinical data for multiple ADCs, including IM1021, are slated for ASH, with more data expected.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMNM | -16.4% | -12.8% | -18.9% | -13.8% | -27.0% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -7.9% | -3.6% | -9.7% | -5.1% | -28.1% |